愛美醫療 FOLD 深 滬
等待開盤 02-06 09:30:00 美东时间
14.28
+0.010
+0.07%
華盛通- 最 高14.29
- 今 開14.27
- 成交量 443.56万股
- 最 低 14.26
- 昨 收 14.27
- 總市值 44.13亿
- 52周最高 14.38
- 市盈率 靜 --
- 換手率 1.44%
- 52周最低 5.51
- 委 比 82.27%
- 總股本 3.09亿
- 歷史最高 25.39
- 量 比 0.65
- 振 幅 0.21%
- 歷史最低 1.765
- 每 手 1
- 風險率 2.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Amicus Therapeutics präsentiert neue Langzeitdaten zu Galafold und Pombiliti + Opfolda
Amicus Therapeutics präsentiert neue Langzeitdaten zu Galafold und Pombiliti + Opfolda Amicus Therapeutics Inc. hat die Präsentation neuer Daten aus klinischen und Real-World-Studien zu Galafold® (Migalastat) für die Behandlung der Fabry-Krankheit sowie zu POMBILITI® (Cipaglucosidase alfa) + OPFOLDA
02-03 21:01
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026
Amicus Therapeutics announced new data from clinical and real-world studies of Galafold and Pombiliti + Opfolda in Fabry and late-onset Pompe diseases at the 22nd Annual WORLD Symposium 2026. The data highlight long-term efficacy and safety, with Galafold showing benefits in Fabry patients and Pombiliti + Opfolda demonstrating improvements in muscle function and biomarkers in Pompe patients. The company emphasized its commitment to advancing trea...
02-03 13:00
Top 3 Health Care Stocks That May Implode In Q1
As of Feb. 2, 2026, three stocks in the health care sector could be flashing a ...
02-02 18:29
BioMarin to Acquire Amicus Therapeutics in Proposed Deal
BioMarin to Acquire Amicus Therapeutics in Proposed Deal BioMarin Pharmaceutical Inc. is moving forward with its previously announced plan to acquire Amicus Therapeutics, Inc. In an update, Amicus disclosed that as of December 31, 2025, it had approximately $294 million in cash, cash equivalents, an
01-26 21:12
美股大行评级 | 潜在涨幅258.31%！Tempest Therapeutics获HC Wainwright上调评级至"买入"，目标价11美元
今日重点评级关注：HC Wainwright & Co.：上调Tempest Therapeutics评级至"买入"，目标价11美元；Guggenheim：维持Sportradar Gr"买入"评级，目标价从34美元升至35美元
01-23 19:46
Amicus Therapeutics CEO Bradley L. Campbell Reports Disposal of Common Shares
Amicus Therapeutics CEO Bradley L. Campbell Reports Disposal of Common Shares Bradley L. Campbell, President and CEO of Amicus Therapeutics Inc., reported a disposal of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was created by Pu
01-23 08:27
Jefferies Downgrades Amicus Therapeutics to Hold, Lowers Price Target to $14.5
Jefferies analyst Dennis Ding downgrades Amicus Therapeutics (NASDAQ:FOLD) from Buy to Hold and lowers the price target from $16 to $14.5.
01-22 21:15
U.S. RESEARCH ROUNDUP-Cencora, Crocs, Teledyne Technologies
U.S. RESEARCH ROUNDUP-Cencora, Crocs, Teledyne Technologies Jan 22 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cencora, Crocs and Teledyne Technologies, on Thursday. HIGHLIGHTS * Cencora COR.N : Jefferies raises to b
01-22 15:17
Amicus Therapeutics Inc. Announces Date for Special Stockholders Meeting
Amicus Therapeutics Inc. Announces Date for Special Stockholders Meeting Amicus Therapeutics Inc. has announced that it will hold a special meeting of stockholders virtually via live webcast in 2026. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial in
01-22 05:19
All J.P. Morgan's top stock picks for 2026
J.P. Morgan identifies specific traits that define their Best Ideas for 2026. These companies typically possess: Strong Financial Health: Robust balance sheets and strong free cash flow generation. Pr...
01-01 01:44
